43 results about "Arrhythmic risk" patented technology

A system and method for monitoring electrical dispersion of the heart is provided including an implantable medical device and associated electrode system for sensing cardiac signals from a combination of two or more local and/or global EGM sensing vectors and/or subcutaneous ECG sensing vectors. Activation and recovery times and the activation-recovery intervals are measured from a selected cardiac cycle for each sensing vector. Dispersion is determined as the differences between activation times, recovery times and/or ARIs measured from each of the sensing vectors. An increase in dispersion indicates a worsening of heart failure and/or an increased risk of arrhythmias. Accordingly, a cardiac therapy may be delivered or adjusted in response to a detected increase in dispersion.

A method of assessing the cardiac arrhythmia risk in a subject to provide a measure of cardiac or cardiovascular health in that subject is described herein. In one embodiment, the method comprises the steps of: (a) collecting at least one QT and RR interval data set from the subject; (b) separating fluctuations from slow trends in said at least one QT and RR interval data set; (c) comparing said QT and RR fluctuations to one another and (d) generating from the comparison of step (c) partial measures of risk of cardiac arrhythmia in said subject. A greater difference between QT and RR fluctuations indicates greater risk of cardiac arrhythmia in said subject. The data sets are collected in such a manner that they reflect almost exclusively the conduction in the heart muscle and minimize the effect on the data sets of rapid transients due to autonomic nervous system and hormonal control.

Electrical activity can be chronically detected in first and second cardiac regions in the subject. Discordant alternans in at least one component of the detected electrical activity can by identified. Interventional therapy can be initiated in the subject responsive to the identification of discordant alternans.

An implantable device and method for monitoring changes in the risk of arrhythmia induced by medications. The implantable device monitors risk of arrhythmia by analyzing an aspect of T-wave morphology to generate a metric of transmural dispersion of repolarization (“TDR”) as a proxy for the risk of arrhythmia. The implantable device generates an index of change in the risk of arrhythmia by comparing values of the metric of TDR obtained for different time periods. The implantable device generates a warning if the change in risk of arrhythmia is outside acceptable limits. The implantable device can also communicate with other devices to correlate changes in risk of arrhythmia with medications taken by the patient.

A method and system for predicting the onset of heart arrhythmias more accurately observes trends in abnormal or pathologic morphology of the electrocardiogram (ECG). A first set of ECG signals is monitored from a patient. A baseline measurement is generated from the monitored first set of ECG signals to contain nonpathologic ECG morphologies in each lead. A second set of ECG signals is monitored from the patient and the baseline measurement is subtracted from the second set of ECG signals on a beat-to-beat basis. Afterwards, a residuum signal is generated for each lead based on the subtraction. R-wave heterogeneity, T-wave heterogeneity, P-wave heterogeneity, or ST-segment heterogeneity or other indicators of arrhythmia risk or myocardial ischemia are quantified based on the generated residuum signals.

The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.

A method of predicting ventricular arrhythmias includes receiving an electrical signal from a subject's heart for a plurality of heart beats, identifying characteristic intervals and heart beat durations of the electrical signal corresponding to each of the plurality of heart beats to provide a plurality of characteristic intervals with corresponding heart beat durations, representing dynamics of the plurality of characteristic intervals as a function of a plurality of preceding characteristic intervals and durations of corresponding heart beats over a chosen period time, assessing a stability of the function over the chosen period of time, and predicting ventricular arrhythmias based on detected instabilities in the dynamics of the characteristic intervals.

A method and system for high-throughput prediction of the onset of heart arrhythmias observes trends in abnormal or pathologic morphology of the electrocardiogram (ECG). A first set of ECG signals is monitored from a patient. A baseline measurement is generated from the monitored first set of ECG signals to contain nonpathologic ECG morphologies in each lead. A second set of ECG signals is monitored from the patient and a second baseline measurement is generated from the second set of ECG signals. A residuum signal is generated for each lead based on the baseline measurement and the second baseline measurement. The residuum signals are averaged across the leads. R-wave heterogeneity, T-wave heterogeneity, P-wave heterogeneity, or ST-segment heterogeneity or other indicators of arrhythmia risk or myocardial ischemia are quantified based on the generated residuum signals and the averaged residuum signal.

The present invention relates to markers and methods for determining risk of ventricular arrhythmia in an individual. By using the markers of the present invention, individual with high risk of ventricular arrhythmia can properly be detected and treated. The present inventors have discovered that IL-6 and/or DROMs have strongly positive correlation with the risk of ventricular arrhythmia.

The present invention relates to a method of determining the risk of drug induced arrhythmia using stem cell derived cardiomyocytes in a high-throughput impedance or multi-electrode array assay.

The Cardiac Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

An implantable bi-ventricular heart stimulating device and system operate, within a time cycle, to deliver pacing pulses with both a first and a second pacing circuit with a first time delay between these pacing pulses. The device employs a criterion with which a signal typical for a premature ventricular contraction is detected. The device also operates with a second time delay and/or with a third time delay, and, if a predefined pacing rule is fulfilled, to deliver a pacing pulse with the second time delay or said third time delay. The risk for arrhythmia in connection with a PVC is reduced.